LAURA J CHONG M.D.
Prescription History 1831133313
Obstetrics & Gynecology in Salem, OR

NPI Status: Active since June 15, 2006

Contact Information

2020 CAPITOL ST NE
SALEM, OR
ZIP 97303
Phone: (503) 399-2424
Fax: (503) 375-7429

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for LAURA J CHONG M.D., an active Obstetrics & Gynecology specialist practicing in Salem, OR. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 254 documented patient claims. Among these therapy options, the most frequently utilized medication is Solifenacin Succinate, which accounts for 86 claims alone.


Clobetasol Propionate

Generic Formulation: Clobetasol PropionateSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 13
30-Day Fills 22.3
Days Supply 653
OR State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills42.2
Peer Average Days Supply1,076
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.9% less volume than the regional standard for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $579.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$44.61

State Avg Cost Per Claim

$57.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A derivative of PREDNISOLONE with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than FLUOCINONIDE, it is used topically in treatment of PSORIASIS but may cause marked adrenocortical suppression.

Therapeutic Applications

This medication is used to treat a variety of skin conditions (such as eczema, psoriasis, dermatitis, allergies, rash). Clobetasol reduces the swelling, itching, and redness that can occur in these types of conditions. This medication is a very strong (super-high-potency) corticosteroid.

Estradiol

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 58
30-Day Fills 226.9
Days Supply 6,805
OR State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills80.4
Peer Average Days Supply2,405
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 87.1% higher than the standard regional baseline profile for OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,622.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$114.18

State Avg Cost Per Claim

$70.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Myrbetriq

Generic Formulation: MirabegronSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 26
30-Day Fills 40.0
Days Supply 1,200
OR State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills54.7
Peer Average Days Supply1,594
Conservative Utilization

This provider writes prescriptions for this formulation 25.7% less frequently than the standard regional baseline metric for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,396.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$669.09

State Avg Cost Per Claim

$676.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Oxybutynin Chloride Er

Generic Formulation: Oxybutynin ChlorideSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 26
30-Day Fills 55.6
Days Supply 1,670
OR State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills49.7
Peer Average Days Supply1,476
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,047.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$40.30

State Avg Cost Per Claim

$38.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This is a long-acting form of oxybutynin that is used to treat overactive bladder and urinary conditions. It relaxes the muscles in the bladder to help decrease problems of urgency and frequent urination. Oxybutynin belongs to a class of drugs known as antispasmodics. This medication is also used to treat children 6 years of age and older who have an overactive bladder due to certain nerve disorders (such as spina bifida).

Premarin

Generic Formulation: Estrogens, ConjugatedSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 11
30-Day Fills 28.3
Days Supply 826
OR State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills36.9
Peer Average Days Supply1,094
Conservative Utilization

This provider writes prescriptions for this formulation 31.3% less frequently than the standard regional baseline metric for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,989.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$544.49

State Avg Cost Per Claim

$395.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate.

Therapeutic Applications

This medication is a female hormone. It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment. Certain estrogen products may also be used by men and women to treat cancers (certain types of prostate cancer, breast cancer that has spread to other parts of the body) and by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure).

Solifenacin Succinate

Generic Formulation: Solifenacin SuccinateSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 86
30-Day Fills 153.3
Days Supply 4,600
OR State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills47.6
Peer Average Days Supply1,419
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 218.5% higher than the standard regional baseline profile for OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,451.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$75.01

State Avg Cost Per Claim

$59.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinuclidine and tetrahydroisoquinoline derivative and selective M3 MUSCARINIC ANTAGONIST. It is used as a UROLOGIC AGENT in the treatment of URINARY INCONTINENCE.

Therapeutic Applications

Solifenacin is used to treat an overactive bladder. By relaxing the muscles in the bladder, solifenacin improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. This medication belongs to the class of drugs known as antispasmodics.

Tolterodine Tartrate Er

Generic Formulation: Tolterodine TartrateSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 34
30-Day Fills 44.0
Days Supply 1,300
OR State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills31.5
Peer Average Days Supply930
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 70.0% higher than the standard regional baseline profile for OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,741.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$51.21

State Avg Cost Per Claim

$141.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An ANTIMUSCARINIC AGENT selective for the MUSCARINIC RECEPTORS of the BLADDER that is used in the treatment of URINARY INCONTINENCE and URINARY URGE INCONTINENCE.

Therapeutic Applications

This medication is used to treat an overactive bladder. By relaxing the muscles in the bladder, tolterodine improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. This medication belongs to the class of drugs known as antispasmodics.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like LAURA J CHONG M.D. provides transparency into local medical care patterns within Salem, OR.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Obstetrics & Gynecology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.